Goal achievement of HbA1c and LDL-cholesterol in a randomized trial comparing colesevelam with ezetimibe: GOAL-RCT.

Autor: Bajaj HS; LMC Diabetes & Endocrinology, Toronto, Ontario, Canada.; Leadership Sinai Center for Diabetes, Mount Sinai Hospital, Toronto, Ontario, Canada., Brown RE; LMC Diabetes & Endocrinology, Toronto, Ontario, Canada., Jiandani D; LMC Diabetes & Endocrinology, Toronto, Ontario, Canada., Venn K; LMC Diabetes & Endocrinology, Toronto, Ontario, Canada., Al-Asaad H; LMC Diabetes & Endocrinology, Toronto, Ontario, Canada., Khandwala H; LMC Diabetes & Endocrinology, Toronto, Ontario, Canada., Steen O; LMC Diabetes & Endocrinology, Toronto, Ontario, Canada., Abdel-Salam S; LMC Diabetes & Endocrinology, Toronto, Ontario, Canada., Aronson R; LMC Diabetes & Endocrinology, Toronto, Ontario, Canada.
Jazyk: angličtina
Zdroj: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2020 Oct; Vol. 22 (10), pp. 1722-1728. Date of Electronic Publication: 2020 Jun 18.
DOI: 10.1111/dom.14084
Abstrakt: Aim: To compare the efficacy and safety of colesevelam and ezetimibe as second-line low density lipoprotein-cholesterol (LDL-c)-lowering options in type 2 diabetes (T2D).
Materials and Methods: GOAL-RCT is a 24-week, open-label, randomized, pragmatic clinical trial. Subjects with T2D with uncontrolled HbA1c (7.1%-10%) and LDL-c (>2.0 mmol/L) were randomized 1:1 to colesevelam 3.75 g or ezetimibe 10 mg daily. The primary composite outcome was the proportion of participants achieving an LDL-c target of ≤2.0 mmol/L and HbA1c target of ≤7.0%. Intention to treat analysis was performed.
Results: Two hundred subjects were enrolled: mean age 59 ± 10 years; mean HbA1c 8.0%; mean LDL-c 2.5 mmol/L; 97% on statin therapy. The primary composite outcome was achieved by similar proportions of participants with colesevelam (14.6%) and ezetimibe (10.5%) (P non-inferiority  < .001, P superiority = .41). LDL-c reduction from baseline was less with colesevelam compared with ezetimibe (14.0% vs. 23.2%, P < .01), as was the proportion of subjects achieving an LDL-c target of ≤2.0 mmol/L (47.6% and 67.0%, respectively; P = .007). Mean HbA1c was reduced with colesevelam (-0.26 ± 0.10%), while no change was observed with ezetimibe (difference P = .06). Adverse events and discontinuation rates were higher for colesevelam (20.2% and 31.1%) compared with ezetimibe (7.2% and 6.2%), respectively.
Conclusions: Among subjects with T2D, the initiation of colesevelam or ezetimibe led to similar achievement of primary composite outcome (LDL-c and HbA1c within target), with ezetimibe recording a greater LDL-c reduction and better tolerability than colesevelam.
(© 2020 John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz: